Guidant gains FDA nod for ENDOTAK ICD (implantable cardioverter defibrillator) lead:
This article was originally published in Clinica
Guidant has gained FDA go-ahead to market in the US its ENDOTAK reliance active-fixation defibrillation lead, which it says features a simplified fixation system that allows smooth deployment into the heart wall. The lead, which transmits signals between the heart and the ICD device, has fluoroscopic markers to enable surgeons to clearly see the helix-shaped tip extending into the tissue. The product will be released in the US later this month, said the firm.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.